Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 & #8211; A matched retrospective cohort study

Conclusions: Tocilizumab did not increase the incidence of secondary infection among COVID-19 patients. Larger, randomized trials should evaluate infection as a secondary outcome to validate this finding.

Source: Journal of Global Infectious Diseases - May 31, 2021 Category: Infectious Diseases Authors: Joanna L Moore Stephanie J Stroever Patricia E Rondain Robyn N Scatena Source Type: research